Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T
Department of Obstetrics and Gynecology, Okayama University Medical School, Japan.
Int J Oncol. 2000 Jul;17(1):103-6. doi: 10.3892/ijo.17.1.103.
We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.
我们通过差异聚合酶链反应（PCR）检测了48例上皮性卵巢癌中c-erbB-2和FGF-3基因的扩增情况，并探讨了它们与包括临床结局在内的临床病理特征之间的关联。总体而言，分别有25.0%和20.8%的卵巢癌显示c-erbB-2或FGF-3基因扩增。c-erbB-2基因扩增与特定的组织学细胞类型、较高的组织学分级以及血清CA125水平低显著相关。然而，c-erbB-2基因扩增与患者结局之间没有相关性。在FGF-3基因扩增与任何临床病理特征（包括总生存期）之间未观察到相关性。这些发现表明，c-erbB-2或FGF-3基因扩增可能是卵巢癌发生过程中涉及的致癌事件之一，但不是一个有用的预后标志物。
